What it sells
AI prostate cancer diagnostic.
Business model breakdown
Buyer: who owns the budget?
UnverifiedNHS trusts / radiology and cancer pathway leads.
Trigger: what makes them buy now?
Need to cut missed cancers, unnecessary biopsies and cost in the prostate MRI pathway.
Workflow: what inputs become what output?
Pi AI software analyses prostate MRI scans (95% sensitivity, 67% specificity) enabling same-day MRI then biopsy pathway.
Economics: what it saves and how it charges
Software sold to hospitals, positioned to support physicians, reduce costs and deliver better care.
Distribution: how it reaches customers
Demo-led direct sales ('Book a demo') plus integration partners such as Sectra and Koelis.
Funding history and coverage
| Round date | Stage | Amount | Investors | Source |
|---|---|---|---|---|
| 2026-03-31 | — | $11.4M | — | news.google.com |
Profiles summarize public reporting and company websites. Business-model notes are MaxBC's reading of that material, not confirmed facts; unknowns are left blank rather than guessed. Updated 2026-10-12.